The Essential Guide to Peptide Impurities and 99% Purity

peptide impurities are the molecules in a vial that are not the target sequence, and every synthetic peptide contains some of them.

Peptide impurities are the molecules in a vial that are not the target sequence, and every synthetic peptide contains some of them. A Certificate of Analysis reading “99.3% purity” means 0.7% of the integrated HPLC peak area belongs to something else: deletion sequences, oxidized variants, protecting-group adducts, or diastereomers. A product labeled 90–95% pure carries five to ten times that burden, much of it never identified.

This guide catalogs each impurity class with its origin in solid-phase synthesis, its mass-spectrometry signature, and its effect on binding assays and cell studies. It answers the question researchers ask most often, what does 99% purity mean, separates HPLC purity from net peptide content, and shows how cGMP-guideline manufacturing and independent testing keep peptide impurities below levels that compromise research.

What Are Peptide Impurities and Where Do They Come From?

Modern peptides are built by solid-phase peptide synthesis (SPPS), introduced by R. Bruce Merrifield in 1963. Each amino acid is added in a cycle of Fmoc deprotection, washing, coupling, and washing again, so a 30-residue peptide passes through roughly 60 reactions before cleavage, none of them at exactly 100% efficiency.

Those small inefficiencies compound. At 99% coupling efficiency per step, a 30-residue sequence yields about 74% full-length product; at 98%, only 55%. The remainder is near-identical chains missing one residue, carrying an extra protecting group, or terminated early. Crude purity after cleavage is commonly just 50–80%, so preparative HPLC does the heavy lifting.

Not all peptide impurities come from the synthesis itself. Trifluoroacetic acid remains as a counter-ion, acetonitrile and DMF persist as residual solvents, water binds to the lyophilized cake, and endotoxin or microbial contamination can enter during purification and fill-finish. Our guide to how peptides are made walks through each stage where these process-related impurities arise.

What Does 99% Purity Actually Mean on a COA?

When researchers ask what does 99% purity mean, the precise answer is that it is an HPLC area-percentage statement. The peptide is run on a reversed-phase C18 column with a water/acetonitrile gradient and detected by UV absorbance at 210–220 nm, where the peptide bond absorbs. Software integrates every peak, and purity equals main peak area divided by total area.

Three caveats follow. First, the figure only counts species that absorb UV and elute from the column, so TFA, water, and inorganic salts are invisible to it. Second, impurities that co-elute with the main peak, including diastereomers and some deamidated forms, count as product. Third, it says nothing about identity; a 99% pure peak of the wrong sequence is still 99% pure.

That is why a credible COA pairs HPLC with mass spectrometry confirming the observed molecular weight matches theory (BPC-157 ≈ 1419.5 Da, Semaglutide ≈ 4113.6 Da). For a walkthrough of each field on a certificate, see our guide to peptide purity and how to read a COA.

Which Peptide Impurities Are Most Common in Synthetic Peptides?

The table below summarizes the major classes of peptide impurities by origin, mass shift relative to the intact peptide, detection method, and consequence for a research result.

Table 1: Major classes of peptide impurities with origin, mass signature, detection method, and research consequence.

Deletion Sequences and Truncated Chains

Deletion sequences are the signature impurity of SPPS. When a coupling step fails on a fraction of resin-bound chains, those chains skip a residue but keep growing in every later cycle, yielding a peptide one amino acid short. Because the gap can sit anywhere, a single crude batch may contain dozens of distinct deletion sequences, each differing from the product by one residue mass.

Truncated chains arise when growth stops entirely, usually because manufacturers deliberately cap unreacted amines with acetic anhydride. Capping converts a future deletion sequence into a short, acetylated fragment that separates easily on HPLC. Deletion sequences, by contrast, often elute within seconds of the parent and are the hardest class to purify away. PubMed indexes extensive work on solid-phase peptide synthesis impurities.

Incomplete Deprotection and Cleavage Adducts

Side chains are shielded during synthesis by acid-labile groups: tert-butyl on Ser, Thr, Asp, Glu, and Tyr; Boc on Lys and Trp; Pbf on Arg; trityl on Asn, Gln, Cys, and His. When the final TFA cleavage is too short or scavengers are omitted, some chains retain a group, giving a +56 Da (tBu), +100 Da (Boc), or +252 Da (Pbf) adduct.

Without triisopropylsilane and water to quench them, liberated tert-butyl cations can also alkylate Trp or Met, blocking a side chain that may be a receptor contact point.

Oxidation, Deamidation, and Racemization

Methionine oxidizes to its sulfoxide (+16 Da) on exposure to air, peroxides, or light; a second oxidation gives the sulfone (+32 Da). Asparagine and glutamine deamidate via a succinimide intermediate to Asp, isoAsp, or Glu, a +0.98 Da shift that needs high-resolution MS to resolve. Both reactions continue slowly in the vial; our article on how to tell if a peptide has degraded covers the warning signs.

Racemization is the stealth impurity. During activation, the alpha-carbon of the incoming amino acid can epimerize, especially His, Cys, and Ser, producing a D-residue at one position. The diastereomer has an identical mass and often a nearly identical retention time, so it passes both HPLC and MS. Only chiral amino acid analysis or an orthogonal HPLC method reveals it.

Why Is Residual TFA a Hidden Problem in Cheap Peptides?

Trifluoroacetic acid is indispensable to peptide manufacturing: it cleaves the chain from the resin, strips side-chain protecting groups, and is added at 0.1% to the HPLC mobile phase to sharpen peaks. Every basic site on the peptide, the N-terminus plus each Lys, Arg, and His side chain, leaves purification paired with a 113 Da trifluoroacetate anion.

The quantity is not trivial. TFA in peptides that have not undergone counter-ion exchange commonly accounts for 10–30% of the gross lyophilized weight. A 5 mg vial can therefore hold 0.5–1.5 mg of trifluoroacetate that is invisible to UV-HPLC and never lowers the purity figure. Among peptide impurities, it is the largest by mass and the least often disclosed.

Cornish and colleagues documented the research consequence in 1999, reporting that trace trifluoroacetate inhibited proliferation of osteoblast and chondrocyte cultures in vitro. Later literature on trifluoroacetate and peptide cytotoxicity extends the concern to other cell-based assays. Pharma-grade producers monitor TFA in peptides and, where specified, exchange the counter-ion to acetate or hydrochloride. Gray-market products rarely disclose which salt form is in the vial.

Purity vs Net Peptide Content: Why Both Numbers Matter

HPLC purity and net peptide content answer different questions. Purity asks what fraction of the peptide material is the correct sequence; net peptide content asks what fraction of the total powder is peptide at all. Because counter-ions and bound water are not peptide, net peptide content typically falls between 70% and 90% of gross weight even for a 99% pure product.

Consider a vial labeled 5 mg at 99% purity with 80% net peptide content. It holds about 4.0 mg of peptide, of which roughly 3.96 mg is the target sequence. A researcher who reconstitutes assuming 5 mg of active peptide prepares a stock 20% weaker than intended, and every downstream concentration inherits that error.

Net peptide content is determined by amino acid analysis, nitrogen determination, or UV absorbance. Water content is measured separately by Karl Fischer titration, which quantifies residual moisture in the lyophilized cake, typically a few percent. Together these figures turn a purity percentage into a usable mass.

How Do Peptide Impurities Affect Research Results?

The most direct effect is on concentration accuracy. If a stated 1 mg of peptide contains 20% TFA, 5% water, and 3% deletion sequences, the true mass of target sequence is closer to 0.73 mg. That shifts an apparent EC50 or IC50 by the same factor and compresses a dose-response curve toward higher nominal doses.

The subtler effect is pharmacological. Deletion sequences and single-residue variants of receptor ligands often retain partial affinity and act as weak agonists or competitive antagonists. A 5% impurity with one-tenth the parent’s affinity adds measurable signal at high concentrations, producing biphasic curves misread as receptor heterogeneity. Oxidized Met variants can be nearly inactive, so an oxidized batch reports a falsely low potency.

Process contaminants add a third layer. Endotoxin activates TLR4 and drives cytokine release at picogram-per-milliliter levels, so any inflammation or immune study needs a documented endotoxin result; our peptide endotoxin testing guide explains the LAL assay. Residual solvents, residual TFA in peptides, and elemental impurities independently reduce cell viability. When peptide impurities differ from lot to lot, the same protocol produces different numbers and the biology gets blamed.

The ICH Q3A framework replaces a single purity number with thresholds: a reporting threshold above which every impurity appears on the certificate, an identification threshold above which its structure must be determined, and a qualification threshold above which its biological effect must be assessed. For many drug substances these fall near 0.05%, 0.10%, and 0.15%. That is the logic behind peptide purity standards in pharmaceutical manufacturing, and one a research supplier should borrow.

How Does cGMP Manufacturing Minimize Peptide Impurities?

Current Good Manufacturing Practice, codified in 21 CFR Parts 210 and 211 and in ICH Q7 for active ingredients, treats impurity control as a process-design problem, not a final-inspection problem. Raw materials come first: Fmoc-amino acids are qualified on receipt for identity and enantiomeric purity, because a 0.5% D-isomer in a starting material becomes a 0.5% diastereomer that no purification step will remove.

In-process controls follow. A ninhydrin or chloranil test after each coupling confirms free amines are consumed; difficult residues are double-coupled; unreacted chains are capped with acetic anhydride so they become easily separated truncations rather than deletion sequences. Pseudoproline dipeptides reduce on-resin aggregation in hydrophobic sequences, and cleavage cocktails carry scavengers to suppress tert-butyl adducts.

Purification is where the 99% specification is enforced and most peptide impurities are removed. Preparative reversed-phase HPLC fractions are analyzed individually, and only fractions meeting the target, for example ≥99%, are pooled; the rest is reprocessed rather than blended in to raise yield. Counter-ion exchange, validated lyophilization with controlled residual moisture, and 0.22 µm sterile filtration into depyrogenated Type I glass complete the sequence.

Finally, documentation. Subpart D of 21 CFR 211 requires validated cleaning between products so one peptide never appears as an impurity in the next; Subpart I mandates laboratory controls; Subpart J requires batch records tying every result to a lot number. Our overview of pharmaceutical grade peptides explains why these controls are voluntary for research-use products, and why adopting them exceeds the requirement.

How PSPeptides Controls and Reports Impurities

PSPeptides manufactures every product in US facilities operating under cGMP guidelines and applies a minimum purity threshold of 99% before any vial ships. Purity is not self-reported: every batch goes to independent, accredited third-party laboratories for HPLC purity and mass spectrometry identity, so the peptide impurities figure on the certificate comes from a lab with no commercial stake in the result.

The screening panel goes beyond the two core assays. Each batch is also tested for heavy metals, endotoxin, sterility, and fentanyl, closing the process-contaminant gap that HPLC alone cannot address. Fentanyl screening is not a pharmacopeial test; it is added because the gray-market supply chain has made it a real concern. These peptide purity standards apply to all 40+ products, backed by a New Jersey-based team of 25 and support seven days a week.

Every result is published. Lot-numbered COAs (for example, PSP-0029123) for batches currently shipping are posted on the Certifications page, organized into Singles, Blends, Topicals, and Oral, with recent lots dated May through August 2026. Any order can be checked against its lot through the verification tool, and if a peptide ever fails the 99%+ purity standard, PSPeptides replaces it free of charge.

For industry context, see our review of which companies offer the highest purity peptides and our guide to third party tested peptides.

Further Reading

For additional peer-reviewed research, see: solid-phase peptide synthesis impurities.

Frequently Asked Questions

What is the difference between purity and net peptide content?

Purity is the HPLC area percentage of the correct sequence relative to all peptide-related peaks. Net peptide content is the fraction of total powder weight that is actually peptide, after subtracting counter-ions such as TFA and bound water. A product can be 99% pure and only 75% net peptide content at the same time.

Can mass spectrometry detect every impurity?

No. Mass spectrometry confirms molecular weight and flags impurities with a mass shift, such as deletion sequences or oxidized residues. It cannot distinguish isobaric diastereomers, and it does not quantify TFA, water, residual solvents, or endotoxin, which require ion chromatography, Karl Fischer titration, headspace GC, and the LAL test respectively.

How much TFA is in a typical research peptide?

Without counter-ion exchange, trifluoroacetate commonly makes up 10–30% of the gross lyophilized weight, depending on how many basic residues the sequence contains. Cornish et al. reported in 1999 that trace trifluoroacetate inhibited osteoblast and chondrocyte proliferation in culture, so the salt form should be known before any cell-based work.

Why do peptide impurities matter if a product is already 99% pure?

Because the remaining 1% is not random. It is concentrated in structural analogs of the target sequence that can bind the same receptor, and it sits alongside process contaminants that HPLC never counts. Knowing which peptide impurities are present, and at what level, is what allows a result to be reproduced with a second lot.

Conclusion: Why the Other 1% Matters

A purity percentage is the beginning of a quality conversation, not the end. The other 1%, or the other 5–10% in a lower-grade product, holds deletion sequences, deprotection adducts, oxidized and deamidated variants, and diastereomers, plus the TFA, water, solvents, endotoxin, and metals that HPLC never sees. Understanding peptide impurities lets a researcher turn a label claim into an accurate concentration and a reproducible result.

PSPeptides exists to make that conversation transparent: US cGMP-guideline manufacturing, 99%+ HPLC purity verified by independent accredited laboratories on every batch, mass spectrometry identity, heavy-metal, endotoxin, sterility, and fentanyl screening, and lot-numbered COAs published for every product. Researchers who need reagents held to pharma-grade quality standards can browse PSPeptides research peptides, from BPC-157 to Retatrutide, with the data in hand before they order.

All PSPeptides products are sold exclusively for research and laboratory use.